125 results on '"Shaffer, Nathan"'
Search Results
102. Plasmodium Falciparum-Associated Anemia in Children at a Large Urban Hospital in Zaire
- Author
-
Hedberg, Katrina, primary, Hightower, Allen, additional, Shaffer, Nathan, additional, Paluku, Kalenga Mbudi, additional, Lyamba, Bongo, additional, Davachi, Farzin, additional, Breman, Joel G., additional, and Nguyen-Dinh, Phuc, additional
- Published
- 1993
- Full Text
- View/download PDF
103. Prevalence and correlates of GB virus C infection in HIV-infected and HIV-uninfected pregnant women in Bangkok, Thailand.
- Author
-
Bhanich Supapol, Wendy, Remis, Robert S., Raboud, Janet, Millson, Margaret, Tappero, Jordan, Kaul, Rupert, Kulkarni, Prasad, McConnell, Michelle S., Philip, A. Mock, McNicholl, Janet M., Roongpisuthipong, Anuvat, Chotpitayasunondh, Tawee, Shaffer, Nathan, and Butera, Salvatore
- Abstract
GB virus C (GBV-C) is an apathogenic virus that has been shown to inhibit HIV replication. This study examined the prevalence and correlates of GBV-C infection and clearance in three cohorts of pregnant women in Thailand. The study population consisted of 1,719 (1,387 HIV-infected and 332 HIV-uninfected) women from three Bangkok perinatal HIV transmission studies. Stored blood was tested for GBV-C RNA, GBV-C antibody, and if RNA-positive, genotype. Risk factors associated with the prevalence of GBV-C infection (defined as presence of GBV-C RNA and/or antibody) and viral clearance (defined as presence of GBV-C antibody in the absence of RNA) among women with GBV-C infection were examined using multiple logistic regression. The prevalence of GBV-C infection was 33% among HIV-infected women and 15% among HIV-uninfected women. GBV-C infection was independently associated (AOR, 95% CI) with an increasing number of lifetime sexual partners (referent-1 partner, 2 partners [1.60, 1.22-2.08], 3-10 partners [1.92, 1.39-2.67], >10 partners [2.19, 1.33-3.62]); injection drug use (5.50, 2.12-14.2); and HIV infection (3.79, 2.58-5.59). Clearance of GBV-C RNA among women with evidence of GBV-C infection was independently associated with increasing age in years (referent <20, 20-29 [2.01, 1.06-3.79] and ≥30 [3.18, 1.53-6.60]), more than 10 lifetime sexual partners (3.05, 1.38-6.75), and HIV infection (0.29, 0.14-0.59). This study found that GBV-C infection is a common infection among Thai women and is associated with HIV infection and both sexual and parenteral risk behaviors. J. Med. Virol. 83:33-44, 2011. © 2010 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
104. THE EPIDEMIOLOGY OF APPENDICITIS AND APPENDECTOMY IN THE UNITED STATES
- Author
-
ADDISS, DAVID G., primary, SHAFFER, NATHAN, additional, FOWLER, BARBARA S., additional, and TAUXE, ROBERT V., additional
- Published
- 1990
- Full Text
- View/download PDF
105. Lack of Association between Human Immunodeficiency Virus Type 1 Antibody in Cervicovaginal Lavage Fluid and Plasma and Perinatal Transmission, in Thailand.
- Author
-
Chuachoowong, Rutt, Shaffer, Nathan, VanCott, Thomas C., Chaisilwattana, Pongsakdi, Siriwasin, Wimol, Waranawat, Naris, Vanprapar, Nirun, Young, Nancy L., Mastro, Timothy D., Lambert, John S., and Robb, Merlin L.
- Subjects
- *
HIV , *VIRAL antibodies - Abstract
Determines the lack of association between human immunodeficiency virus type 1 antibody in cervicovaginal lavage (CVL) fluid and plasma and perinatal transmission in Thailand. HIV gp160-specific antibody; Correlation between HUV-specific antibodies in plasma and CVL samples; Correlation between antibodies and HIV RNA levels in CVL samples; Antibody level and perinatal HIV transmission; Antibody level and zidovudine treatment.
- Published
- 2000
106. Short-Course Antenatal Zidovuine Reduces Both Cervicovaginal Human Immunodeficiency Virus Type 1...
- Author
-
Chuachoowong, Rutt, Shaffer, Nathan, Young, Nancy L., Mock, Philip A., Chearskul, Sanay, Waranawat, Naris, Chaowanachan, Thongpoon, Karon, John, Simonds, R.J., and Mastro, Timothy D.
- Subjects
- *
HIV infection transmission , *IRRIGATION (Medicine) , *AZIDOTHYMIDINE - Abstract
Evaluates the interrelationship among HIV-1 levels in cervicovaginal lavage and plasma, zidovudine treatment and risk of perinatal transmission. Determinants of HIV transmission; Risk factors associated with perinatal transmission; Duration of membrane rupture.
- Published
- 2000
107. A BRIEF ORIGINAL CONTRIBUTION.
- Author
-
Matheson, Pamela B., Weedon, Jeremy, Cappelli, Mark, Abrams, Elaine J., Shaffer, Nathan, Bamji, Mahrukh, Krasinski, Keith, Lambert, Genevieve, Kaul, Aditya, Grimm, Katherine, Hutson, David, and Thomas, Pauline A.
- Published
- 1995
- Full Text
- View/download PDF
108. Low Risk of Mother-to-Child Transmission of Human T Lymphotropic Virus Type II in Non-Breast-Fed Infants.
- Author
-
Kaplan, Jonathan E., Abrams, Elaine, Shaffer, Nathan, Cannon, Robert O., Kaul, Aditya, Krasinski, Keith, Bamji, Mahrukh, Hartley, Trudie M., Roberts, Beverly, Kilbourne, Barbara, Thomas, Polly, Rogers, Martha, and Heneine, Walid
- Abstract
The transmissibility of human T lymphotropic virus (HTLV) type II from mother to child was investigated. Of 236 women enrolled during pregnancy in a study of mother-to-child transmission of human immunodeficiency virus in 1986–1988, 21 (8.9%) were seropositive for HTLV-I/II. All 21 mothers were infected with HTLV-II by synthetic peptide testing and polymerase chain reaction (PCR). HTLV-II-infected women were older (median age, 34 vs. 28 years), more likely to be black (70% vs. 38%), and more likely to report past or current intravenous drug use (85% vs. 56%) than HTLV-II-uninfected women. Of 20 non-breast-fed infants born to 19 of these HTLV-II-infected women, none had detectable HTLV-II by PCR done on peripheral blood mononuclear cells obtained at birth to 36 months of age. Serologic testing of these infants revealed gradual disappearance of HTLV-I/II antibody. While this study does not rule out the possibility of perinatal HTLV-II transmission, the data suggest that it occurs rarely in the absence of breast-feeding. [ABSTRACT FROM PUBLISHER]
- Published
- 1992
109. Role of traditional birth attendants in preventing perinatal transmission of HIV.
- Author
-
Bulterys, Marc, Fowler, Mary Glenn, Shaffer, Nathan, Tih, Pius M, Greenberg, Alan E, Karita, Etienne, Coovadia, Hoosen, and De Cock, Kevin M
- Subjects
MIDWIVES ,PERINATOLOGY ,HIV prevention ,DIAGNOSIS of HIV infections - Abstract
Suggests that traditional birth attendants (TBA) in Africa could be involved in preventing perinatal transmission of HIV by offering services such as HIV testing and counselling, as well as short courses of antitretroviral drugs. Involvement of TBA in preventing HIV transmission; Need for innovative models for prevention of perinatal transmission of HIV involving TBA to develop strategies appropriate to rural settings; Conclusions.
- Published
- 2002
- Full Text
- View/download PDF
110. Human immunodeficiency virus 1specific IgA capture enzyme immunoassay for early diagnosis of human immunodeficiency virus 1 infection in infants
- Author
-
PAREKH, BHARAT S., SHAFFER, NATHAN, COUGHLIN, RICHARD, HUNG, CHUNG-HO, KRASINSKI, KEITH, ABRAMS, ELAINE, BAMJI, MAHRUKH, THOMAS, PAULINE, HUTSON, DAVID, LAMBERT, GENEVIEVE, SCHOCHETMAN, GERALD, ROGERS, MARTHA, and GEORGE, J. RICHARD
- Abstract
A simplified human immunodeficiency virus 1 (HIV-1)-specific IgA capture enzyme immunoassay (IgA-CEIA) was evaluated and compared with IgA-Western blot assay for early diagnosis of HIV-1 infection in infants born to seropositive women. A total of 232 coded sera collected prospectively from 70 infants were tested. All 25 sera from 10 HIV-1-negative in-
- Published
- 1993
111. WHO’s path to elimination of mother-to-child transmission of HIV and syphilis
- Author
-
Shaffer, Nathan, Taylor, Melanie, Newman, Morkor, Nuwagira, Innocent, Bigirimana, Francoise, Regis, Merceline Dahl, Mushavi, Angela, Doherty, Meg, Bulterys, Marc, Askew, Ian, and Hirnschall, Gottfried
- Published
- 2020
- Full Text
- View/download PDF
112. Rapid laboratory diagnosis of cholera in the field
- Author
-
Shaffer, Nathan, primary, do Santos, Epiphanio Silva, additional, Andreason, Per-Ake, additional, and Farmer, J.J., additional
- Published
- 1989
- Full Text
- View/download PDF
113. Elimination of mother-to-child transmission of HIV and syphilis: A dual approach in the African Region to improve quality of antenatal care and integrated disease control.
- Author
-
Newman Owiredu, Morkor, Newman, Lori, Nzomo, Theresa, Conombo Kafando, Ghislaine, Sanni, Saliyou, Shaffer, Nathan, Bucagu, Maurice, Peeling, Rosanna, Mark, Jennifer, and Diop Toure, Isseu
- Published
- 2015
- Full Text
- View/download PDF
114. Reducing the Risk of Maternal–Infant Transmission of HIV by Attacking the Virus.
- Author
-
Rogers, Martha F. and Shaffer, Nathan
- Subjects
- *
HIV infection transmission , *DISEASES in women , *MOTHER-child relationship , *CONTAMINATION of human milk , *PREVENTION of communicable diseases , *SEXUALLY transmitted diseases , *BREASTFEEDING , *PREVENTIVE medicine , *HIV-positive women , *HEALTH , *IMMUNOLOGY - Abstract
The article presents a medical case study. The author reports that the findings of an AIDS Clinical Trials Group (ACTG) Protocol opened the door to a major effort to reduce perinatal infection with the human immunodeficiency virus (HIV). The article states that there has been a decline of more than 60% in the incidence of AIDS in children in the U.S. Additionally, the results of randomized clinical trails conducted in both the developing world and the U.S. indicates that shorter antenatal regimens are effective in reducing the risk of perinatal transmission. The article offers information on various studies conducted on the topic and discusses alternative intervention strategies.
- Published
- 1999
- Full Text
- View/download PDF
115. The evaluation of targeted outreach in an adolescent HIV/AIDS program
- Author
-
Dilorenzo, Terry A., Abramo, Diana M., Hein, Karen, Clare, Glenda S., Dell, Ralph, and Shaffer, Nathan
- Published
- 1993
- Full Text
- View/download PDF
116. First population-level effectiveness evaluation of a national programme to prevent HIV transmission from mother to child, South Africa.
- Author
-
Goga, Ameena E., Thu-Ha Dinh, Jackson, Debra J., Lombard, Carl, Delaney, Kevin P., Puren, Adrian, Sherman, Gayle, Woldesenbet, Selamawit, Ramokolo, Vundli, Crowley, Siobhan, Doherty, Tanya, Chopra, Mickey, Shaffer, Nathan, and Pillay, Yogan
- Subjects
- *
VERTICAL transmission (Communicable diseases) , *CHI-squared test , *CONFIDENCE intervals , *INTERVIEWING , *POPULATION , *RESEARCH funding , *STATISTICAL sampling , *STATISTICS , *MULTIPLE regression analysis , *TREATMENT effectiveness , *EVALUATION of human services programs , *DATA analysis software , *DESCRIPTIVE statistics , *ODDS ratio , *PREVENTION - Abstract
Background There is a paucity of data on the national population-level effectiveness of preventing mother-to-child transmission (PMTCT) programmes in high-HIV-prevalence, resource-limited settings. We assessed national PMTCT impact in South Africa (SA), 2010. Methods A facility-based survey was conducted using a stratified multistage, cluster sampling design. A nationally representative sample of 10 178 infants aged 4–8 weeks was recruited from 565 clinics. Data collection included caregiver interviews, record reviews and infant dried blood spots to identify HIV-exposed infants (HEI) and HIV-infected infants. During analysis, self-reported antiretroviral (ARV) use was categorised: 1a: triple ARV treatment; 1b: azidothymidine >10 weeks; 2a: azidothymidine ≤10 weeks; 2b: incomplete ARV prophylaxis; 3a: no antenatal ARV and 3b: missing ARV information. Findings were adjusted for non-response, survey design and weighted for live-birth distributions. Results Nationally, 32% of live infants were HEI; early mother-to-child transmission (MTCT) was 3.5% (95% CI 2.9% to 4.1%). In total 29.4% HEI were born to mothers on triple ARV treatment (category 1a) 55.6% on prophylaxis (1b, 2a, 2b), 9.5% received no antenatal ARV (3a) and 5.5% had missing ARV information (3b). Controlling for other factors groups, 1b and 2a had similar MTCT to 1a (Ref; adjusted OR (AOR) for 1b, 0.98, 0.52 to 1.83; and 2a, 1.31, 0.69 to 2.48). MTCT was higher in group 2b (AOR 3.68, 1.69 to 7.97). Within group 3a, early MTCT was highest among breastfeeding mothers 11.50% (4.67% to 18.33%) for exclusive breast feeding, 11.90% (7.45% to 16.35%) for mixed breast feeding, and 3.45% (0.53% to 6.35%) for no breast feeding). Antiretroviral therapy or >10 weeks prophylaxis negated this difference (MTCT 3.94%, 1.98% to 5.90%; 2.07%, 0.55% to 3.60% and 2.11%, 1.28% to 2.95%, respectively). Conclusions SA, a high-HIV-prevalence middle income country achieved <5% MTCT by 4–8 weeks post partum. The long-term impact on PMTCT on HIV-free survival needs urgent assessment [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
117. Reduced Mother-to-Child Transmission of HIV Associated with Infant but not Maternal GB Virus C Infection.
- Author
-
Supapol, Wendy Bhanich, Remis, Robert S., Raboud, Janet, Millson, Margaret, Tappero, Jordan, Kaul, Rupert, Kulkarni, Prasad, McConnell, Michelle S., Mock, Philip A., Culnane, Mary, McNicholl, Janet, Roongpisuthipong, Anuvat, Chotpitayasunondh, Tawee, Shaffer, Nathan, and Butera, Salvatore
- Subjects
- *
VIRUSES , *HIV , *HIV infections , *PREGNANT women , *HUMAN experimentation , *HUMAN research subjects , *GENETIC polymorphisms - Abstract
Background. Prolonged coinfection with GB virus C (GBV-C) has been associated with improved survival in human immunodeficiency virus (HIV)-infected adults.Weinvestigated whether maternal or infant GBV-C infection was associated with mother-to-child transmission (MTCT) of HIV-1 infection. Methods. The study population included 1364 HIV-infected pregnant women enrolled in 3 studies of MTCT of HIV in Bangkok, Thailand (the studies were conducted from 1992-1994, 1996-1997, and 1999-2004, respectively). We tested plasma collected from pregnant women at delivery for GBV-C RNA, GBV-C antibody, and GBV-C viral genotype. If GBV-CRNAwas detected in the maternal samples, the 4- or 6-month infant sample was tested for GBV-C RNA. The rates of MTCT of HIV among GBV-C-infected women and infants were compared with the rates among women and infants without GBV-C infection. Results. The prevalence of GBV-C RNA in maternal samples was 19%. Of 245 women who were GBV-C RNA positive, 101 (41%) transmitted GBV-C to their infants. Of 101 infants who were GBV-C RNA positive, 2 (2%) were infected with HIV, compared with 162 (13%) of 1232 infants who were GBV-C RNA negative (odds ratio [OR] adjusted for study, 0.13 [95% confidence interval {CI}, 0.03- 0.54]). This association remained after adjustment for maternal HIV viral load, receipt of antiretroviral prophylaxis, CD4+ count, and other covariates. MTCT of HIV was not associated with the presence of GBV-C RNA (adjusted OR [aOR], 0.94 [95% CI, 0.62-1.42]) or GBV-C antibody (aOR, 0.90 [95% CI, 0.54 -1.50]) in maternal samples. Conclusions. Reduced MTCT of HIV was significantly associated with infant acquisition of GBV-C but not with maternal GBV-C infection. The mechanism for this association remains unknown. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
118. Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus?
- Author
-
Tin Tin Sint, Dabis, François, Kamenga, Claude, Shaffer, Nathan, and de Zoysa, Isabelle F.
- Subjects
- *
HIV-positive women , *AIDS in pregnancy , *PREGNANCY , *INFECTIOUS disease transmission , *PREGNANT women , *HIV-positive persons - Abstract
At present, HIV testing and counselling during pregnancy represent the key entry point for women to learn their serostatus and for them to access, if they are HIV-positive, specific interventions to reduce mother-to-child transmission (MTCT) of HIV. However, the provision and uptake of testing and counselling services are inadequate, and many pregnant women in countries most affected by the HIV/AIDS epidemic remain unaware of their HIV status. The offer of single-dose nevirapine prophylaxis to women whose HIV status is unknown at the time of delivery has been proposed to circumvent these problems in high-prevalence settings. The potential advantages and disadvantages of three different programme approaches are considered: targeted programmes in which antiretroviral drugs are offered only to women who are known to be HIV-positive; combined programmes in which nevirapine prophylaxis is offered to women whose serostatus remains unknown at the time of delivery despite targeted programme inputs; and universal nevirapine prophylaxis programmes in which HIV testing and counselling are not available and all pregnant women, regardless of their serostatus, are offered nevirapine prophylaxis. [ABSTRACT FROM AUTHOR]
- Published
- 2005
119. WHO's path to elimination of mother-to-child transmission of HIV and syphilis.
- Author
-
Shaffer N, Taylor M, Newman M, Nuwagira I, Bigirimana F, Regis MD, Mushavi A, Doherty M, Bulterys M, Askew I, and Hirnschall G
- Subjects
- Child, Female, Humans, Infectious Disease Transmission, Vertical, Pregnancy, Prevalence, HIV Infections, Pregnancy Complications, Infectious, Syphilis
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2020
- Full Text
- View/download PDF
120. Time to first positive HIV-1 DNA PCR may differ with antiretroviral regimen in infants infected with non-B subtype HIV-1.
- Author
-
Balasubramanian R, Fowler MG, Dominguez K, Lockman S, Tookey PA, Huong NNG, Nesheim S, Hughes MD, Lallemant M, Tosswill J, Shaffer N, Sherman G, Palumbo P, and Shapiro DE
- Subjects
- Botswana, DNA, Viral genetics, Female, HIV Infections diagnosis, HIV Infections drug therapy, HIV Infections virology, HIV-1 classification, HIV-1 genetics, Humans, Infant, Infant, Newborn, Male, Polymerase Chain Reaction, Pregnancy, Prospective Studies, Thailand, Time Factors, United Kingdom, Anti-Retroviral Agents therapeutic use, Antiretroviral Therapy, Highly Active methods, Chemoprevention methods, DNA, Viral blood, Genotype, HIV Infections prevention & control, HIV-1 isolation & purification
- Abstract
Objective: To evaluate the association of type and timing of prophylactic maternal and infant antiretroviral regimen with time to first positive HIV-1 DNA PCR test, in nonbreastfed HIV-infected infants, from populations infected predominantly with HIV-1 non-B subtype virus., Design: Analysis of combined data on nonbreastfed HIV-infected infants from prospective cohorts in Botswana, Thailand, and the United Kingdom (N = 405)., Methods: Parametric models appropriate for interval-censored outcomes estimated the time to first positive PCR according to maternal or infant antiretroviral regimen category and timing of maternal antiretroviral initiation, with adjustment for covariates., Results: Maternal antiretroviral regimens included: no antiretrovirals (n = 138), single-nucleoside analog reverse transcriptase inhibitor (n = 165), single-dose nevirapine with zidovudine (n = 66), and combination prophylaxis with 3 or more antiretrovirals [combination antiretroviral therapy (cART), n = 36]. Type of maternal/infant antiretroviral regimen and timing of maternal antiretroviral initiation were each significantly associated with time to first positive PCR (multivariate P < 0.0001). The probability of a positive test with no antiretrovirals compared with the other regimen/timing groups was significantly lower at 1 day after birth, but did not differ significantly after age 14 days. In a subgroup of 143 infants testing negative at birth, infant cART was significantly associated with longer time to first positive test (multivariate P = 0.04)., Conclusion: Time to first positive HIV-1 DNA PCR in HIV-1-infected nonbreastfed infants (non-B HIV subtype) may differ according to maternal/infant antiretroviral regimen and may be longer with infant cART, which may have implications for scheduling infant HIV PCR-diagnostic testing and confirming final infant HIV status.
- Published
- 2017
- Full Text
- View/download PDF
121. Implementation and Operational Research: Reconstructing the PMTCT Cascade Using Cross-sectional Household Survey Data: The PEARL Study.
- Author
-
Chi BH, Tih PM, Zanolini A, Stinson K, Ekouevi DK, Coetzee D, Welty TK, Bweupe M, Shaffer N, Dabis F, Stringer EM, and Stringer JS
- Subjects
- Adult, Africa, Child, Preschool, Communicable Disease Control organization & administration, Cross-Sectional Studies, Family Characteristics, Female, Humans, Infant, Infant, Newborn, Male, Pregnancy, Young Adult, Communicable Disease Control methods, HIV Infections prevention & control, HIV Infections transmission, Infectious Disease Transmission, Vertical prevention & control
- Abstract
Background: Given the ambitious targets to reduce pediatric AIDS worldwide, ongoing assessment of programs to prevent mother-to-child HIV transmission (PMTCT) is critical. The concept of a "PMTCT cascade" has been used widely to identify bottlenecks in program implementation; however, most efforts to reconstruct the cascade have relied on facility-based approaches that may limit external validity., Methods: We analyzed data from the PEARL household survey, which measured PMTCT effectiveness in 26 communities across Zambia, South Africa, Cote d'Ivoire, and Cameroon. We recruited women who reported a delivery in the past 2 years. Among mothers confirmed to be HIV infected at the time of survey, we reconstructed the PMTCT cascade with self-reported participant information. We also analyzed data about the child's vital status; for those still alive, HIV testing was performed by DNA polymerase chain reaction testing., Results: Of the 976 eligible women, only 355 (36%) completed every step of the PMTCT cascade. Among the 621 mother-child pairs who did not, 22 (4%) reported never seeking antenatal care, 103 (17%) were not tested for HIV during pregnancy, 395 (64%) reported testing but never received their HIV-positive result, 48 (8%) did not receive maternal antiretroviral prophylaxis, and 53 (9%) did not receive infant antiretroviral prophylaxis. The lowest prevalence of infant HIV infection or death was observed in those completing the cascade (10%, 95% confidence interval: 7% to 12%)., Conclusions: Future efforts to measure population PMTCT impact should incorporate dimensions explored in the PEARL study-including HIV testing of HIV-exposed children in household surveys-to better understand program effectiveness.
- Published
- 2015
- Full Text
- View/download PDF
122. The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV.
- Author
-
O'Brien L, Shaffer N, Sangrujee N, and Abimbola TO
- Subjects
- Anti-HIV Agents, Anti-Retroviral Agents therapeutic use, Breast Feeding, CD4 Lymphocyte Count, Cohort Studies, Cost-Benefit Analysis, Female, HIV Infections blood, HIV Infections prevention & control, HIV Infections transmission, Humans, Nevirapine economics, Nevirapine therapeutic use, Pregnancy, United Nations, United States, Anti-Retroviral Agents economics, HIV Infections drug therapy, HIV Infections economics, Infectious Disease Transmission, Vertical economics, Infectious Disease Transmission, Vertical prevention & control
- Abstract
Objective: To estimate the incremental cost over 5 years of a policy switch from the Option B to the Option B+ protocol for the prevention of mother-to-child transmission (PMTCT) of the human immunodeficiency virus (HIV)., Methods: Data from cost studies and other published sources were used to determine the cost, per woman and per cohort (1000 breastfeeding and 1000 non-breastfeeding women), of switching from Option B (maternal triple antiretroviral [ARV] regimen during pregnancy and breastfeeding plus daily nevirapine for the infant for 6 weeks) to Option B+ (maternal triple ARV regimen initiated during pregnancy and continued for life). The variables used to model the different scenarios were maternal CD4+ T lymphocyte (CD4+ cell) count (350-500 versus > 500 cells/µl), rate of decline in CD4+ cells (average, rapid, slow), breastfeeding status (yes, no) and breastfeeding duration (12, 18 or 24 months)., Findings: For women with CD4+ cell counts of 350-500 cells/µl, the incremental cost per 1000 women was 157,345 United States dollars (US$) for breastfeeding women and US$ 92,813 for non-breastfeeding women. For women with CD4+ cell counts > 500 cells/µl, the incremental cost per 1000 women ranged from US$ 363,443 to US$ 484,591 for breastfeeding women and was US$ 605,739 for non-breastfeeding women., Conclusion: From a cost perspective, a policy switch from Option B to Option B+ is feasible in PMTCT programme settings where resources are currently being allocated to Option B.
- Published
- 2014
- Full Text
- View/download PDF
123. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
- Author
-
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, and Hallett TB
- Subjects
- Adult, CD4 Lymphocyte Count, Cost-Benefit Analysis, Eligibility Determination methods, Female, HIV Infections immunology, Health Care Costs, Humans, India, Male, Models, Theoretical, Quality-Adjusted Life Years, South Africa, Vietnam, Zambia, Antiretroviral Therapy, Highly Active economics, HIV Infections drug therapy
- Abstract
Background: New WHO guidelines recommend initiation of antiretroviral therapy for HIV-positive adults with CD4 counts of 500 cells per μL or less, a higher threshold than was previously recommended. Country decision makers have to decide whether to further expand eligibility for antiretroviral therapy accordingly. We aimed to assess the potential health benefits, costs, and cost-effectiveness of various eligibility criteria for adult antiretroviral therapy and expanded treatment coverage., Methods: We used several independent mathematical models in four settings-South Africa (generalised epidemic, moderate antiretroviral therapy coverage), Zambia (generalised epidemic, high antiretroviral therapy coverage), India (concentrated epidemic, moderate antiretroviral therapy coverage), and Vietnam (concentrated epidemic, low antiretroviral therapy coverage)-to assess the potential health benefits, costs, and cost-effectiveness of various eligibility criteria for adult antiretroviral therapy under scenarios of existing and expanded treatment coverage, with results projected over 20 years. Analyses assessed the extension of eligibility to include individuals with CD4 counts of 500 cells per μL or less, or all HIV-positive adults, compared with the previous (2010) recommendation of initiation with CD4 counts of 350 cells per μL or less. We assessed costs from a health-system perspective, and calculated the incremental cost (in US$) per disability-adjusted life-year (DALY) averted to compare competing strategies. Strategies were regarded very cost effective if the cost per DALY averted was less than the country's 2012 per-head gross domestic product (GDP; South Africa: $8040; Zambia: $1425; India: $1489; Vietnam: $1407) and cost effective if the cost per DALY averted was less than three times the per-head GDP., Findings: In South Africa, the cost per DALY averted of extending eligibility for antiretroviral therapy to adult patients with CD4 counts of 500 cells per μL or less ranged from $237 to $1691 per DALY averted compared with 2010 guidelines. In Zambia, expansion of eligibility to adults with a CD4 count threshold of 500 cells per μL ranged from improving health outcomes while reducing costs (ie, dominating the previous guidelines) to $749 per DALY averted. In both countries results were similar for expansion of eligibility to all HIV-positive adults, and when substantially expanded treatment coverage was assumed. Expansion of treatment coverage in the general population was also cost effective. In India, the cost for extending eligibility to all HIV-positive adults ranged from $131 to $241 per DALY averted, and in Vietnam extending eligibility to patients with CD4 counts of 500 cells per μL or less cost $290 per DALY averted. In concentrated epidemics, expanded access for key populations was also cost effective., Interpretation: Our estimates suggest that earlier eligibility for antiretroviral therapy is very cost effective in low-income and middle-income settings, although these estimates should be revisited when more data become available. Scaling up antiretroviral therapy through earlier eligibility and expanded coverage should be considered alongside other high-priority health interventions competing for health budgets., Funding: Bill & Melinda Gates Foundation, WHO., (Copyright © 2014 Eaton et al. Open Access article distributed under the terms of CC BY-NC-ND. Published by .. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
124. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
- Author
-
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, and Hallett TB
- Abstract
Background: New WHO guidelines recommend ART initiation for HIV-positive persons with CD4 cell counts ≤500 cells/µL, a higher threshold than was previously recommended. Country decision makers must consider whether to further expand ART eligibility accordingly., Methods: We used multiple independent mathematical models in four settings-South Africa, Zambia, India, and Vietnam-to evaluate the potential health impact, costs, and cost-effectiveness of different adult ART eligibility criteria under scenarios of current and expanded treatment coverage, with results projected over 20 years. Analyses considered extending eligibility to include individuals with CD4 ≤500 cells/µL or all HIV-positive adults, compared to the previous recommendation of initiation with CD4 ≤350 cells/µL. We assessed costs from a health system perspective, and calculated the incremental cost per DALY averted ($/DALY) to compare competing strategies. Strategies were considered 'very cost-effective' if the $/DALY was less than the country's per capita gross domestic product (GDP; South Africa: $8040, Zambia: $1425, India: $1489, Vietnam: $1407) and 'cost-effective' if $/DALY was less than three times per capita GDP., Findings: In South Africa, the cost per DALY averted of extending ART eligibility to CD4 ≤500 cells/µL ranged from $237 to $1691/DALY compared to 2010 guidelines; in Zambia, expanded eligibility ranged from improving health outcomes while reducing costs (i.e. dominating current guidelines) to $749/DALY. Results were similar in scenarios with substantially expanded treatment access and for expanding eligibility to all HIV-positive adults. Expanding treatment coverage in the general population was therefore found to be cost-effective. In India, eligibility for all HIV-positive persons ranged from $131 to $241/DALY and in Vietnam eligibility for CD4 ≤500 cells/µL cost $290/DALY. In concentrated epidemics, expanded access among key populations was also cost-effective., Interpretation: Earlier ART eligibility is estimated to be very cost-effective in low- and middle-income settings, although these questions should be revisited as further information becomes available. Scaling-up ART should be considered among other high-priority health interventions competing for health budgets., Funding: The Bill and Melinda Gates Foundation and World Health Organization.
- Published
- 2013
- Full Text
- View/download PDF
125. Role of traditional birth attendants in preventing perinatal transmission of HIV.
- Author
-
Bulterys M, Fowler MG, Shaffer N, Tih PM, Greenberg AE, Karita E, Coovadia H, and De Cock KM
- Subjects
- Developing Countries, Female, HIV Infections transmission, Humans, Infant, Newborn, Models, Nursing, Organizational Innovation, Pregnancy, HIV Infections prevention & control, Infectious Disease Transmission, Vertical prevention & control, Midwifery organization & administration, Pregnancy Complications, Infectious
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.